We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current ARQT market cap is 1.8B. The company's latest EPS is USD -1.1804 and P/E is -12.64.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 13.53M | 49.57M | 30.86M | 44.76M | 71.36M |
| Operating Income | -61.17M | -31.62M | -50.08M | -39.07M | -7.63M |
| Net Income | -66.28M | -35.38M | -52.33M | -41.54M | -10.79M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 3.69M | 59.61M | 196.54M |
| Operating Income | -136.65M | -206.53M | -301.63M | -241.1M | -128.4M |
| Net Income | -135.68M | -206.36M | -311.46M | -262.14M | -140.04M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 341.37M | 478.54M | 444.76M | 437.35M | 348.89M |
| Total Liabilities | 252.7M | 253.6M | 258.33M | 280.71M | 191.35M |
| Total Equity | 88.67M | 224.94M | 186.43M | 156.64M | 157.54M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 298.27M | 408.15M | 449.27M | 341.37M | 348.89M |
| Total Liabilities | 27.65M | 110.48M | 239.69M | 252.7M | 191.35M |
| Total Equity | 270.62M | 297.68M | 209.58M | 88.67M | 157.54M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -247.06M | -31.6M | -76.72M | -111.41M | -112.16M |
| Investing | 180.23M | -28.7M | -90.83M | -6.06M | 28.82M |
| Financing | 101.32M | 161.76M | 163.22M | 163.61M | 66.2M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -113.03M | -174.63M | -257.72M | -247.06M | -112.16M |
| Investing | -181.82M | -75.95M | -87.2M | 180.23M | 28.82M |
| Financing | 298.15M | 281.95M | 301.8M | 101.32M | 66.2M |
| Market Cap | 1.8B |
| Price to Earnings Ratio | -12.64 |
| Price to Sales Ratio | 9.01 |
| Price to Cash Ratio | 24.81 |
| Price to Book Ratio | 11.24 |
| Dividend Yield | - |
| Shares Outstanding | 118.64M |
| Average Volume (1 week) | 2.06M |
| Average Volume (1 Month) | 2.4M |
| 52 Week Change | 50.96% |
| 52 Week High | 16.20 |
| 52 Week Low | 6.99 |
| Spread (Intraday) | 0.05 (0.33%) |
| Company Name | Arcutis Biotherapeutics Inc |
| Address |
3411 silverside road tatnall wilmington, delaware 19810 |
| Website | https://www.arcutis.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
